{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T17:25:37Z","timestamp":1758216337891,"version":"3.44.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP 1122332"],"award-info":[{"award-number":["APP 1122332"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153275"],"award-info":[{"award-number":["PJT-153275"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40290-025-00573-y","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:42:43Z","timestamp":1750862563000},"page":"353-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety Warnings on the Same Harmful Effects of Medicines: A Comparison of Four National Regulators"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-1321","authenticated-orcid":false,"given":"Lucy T.","family":"Perry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-8760","authenticated-orcid":false,"given":"Alice","family":"Bhasale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-1837","authenticated-orcid":false,"given":"Ashleigh","family":"Hooimeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-3474","authenticated-orcid":false,"given":"Eliza J.","family":"McEwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-2219","authenticated-orcid":false,"given":"Annim","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-915X","authenticated-orcid":false,"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"573_CR1","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/cpt.2010","volume":"109","author":"AL Bhasale","year":"2021","unstructured":"Bhasale AL, Sarpatwari A, De Bruin ML, et al. Postmarket safety communication for protection of public health: a comparison of regulatory policy in Australia, Canada, the European Union, and the United States. Clin Pharmacol Ther. 2021;109:1424\u201342. https:\/\/doi.org\/10.1002\/cpt.2010.","journal-title":"Clin Pharmacol Ther"},{"key":"573_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109100","volume":"9","author":"J-D Zeitoun","year":"2014","unstructured":"Zeitoun J-D, Lef\u00e8vre JH, Downing N, et al. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison. PLoS ONE. 2014;9: e109100. https:\/\/doi.org\/10.1371\/journal.pone.0109100.","journal-title":"PLoS ONE"},{"key":"573_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5072","author":"LT Perry","year":"2020","unstructured":"Perry LT, Bhasale A, Fabbri A, et al. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States: 2007 to 2016. Pharmacoepidemiol Drug Saf. 2020. https:\/\/doi.org\/10.1002\/pds.5072.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamainternmed.2019.0294","volume":"179","author":"LT Perry","year":"2019","unstructured":"Perry LT, Bhasale A, Fabbri A, et al. Comparative analysis of medicines safety advisories released by Australia, Canada, the United States, and the United Kingdom. JAMA Intern Med. 2019;179:982. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0294.","journal-title":"JAMA Intern Med"},{"key":"573_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020150","volume":"8","author":"LM Bjerre","year":"2018","unstructured":"Bjerre LM, Parlow S, de Launay D, et al. Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK. BMJ Open. 2018;8: e020150. https:\/\/doi.org\/10.1136\/bmjopen-2017-020150.","journal-title":"BMJ Open"},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/11319870-000000000-00000","volume":"33","author":"HE Heemstra","year":"2010","unstructured":"Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, et al. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. Drug Saf. 2010;33:127\u201337. https:\/\/doi.org\/10.2165\/11319870-000000000-00000.","journal-title":"Drug Saf"},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.300.16.1887","volume":"300","author":"T Giezen","year":"2008","unstructured":"Giezen T, Mantel-Teeuwisse A, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300:1887. https:\/\/doi.org\/10.1001\/jama.300.16.1887.","journal-title":"JAMA"},{"key":"573_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1107","volume":"369","author":"A Bhasale","year":"2020","unstructured":"Bhasale A, Mintzes B, Sarpatwari A. Communicating emerging risks of SGLT2 inhibitors: timeliness and transparency of medicine regulators. BMJ. 2020;369: m1107. https:\/\/doi.org\/10.1136\/bmj.m1107.","journal-title":"BMJ"},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/11599100-000000000-00000","volume":"35","author":"S Piening","year":"2012","unstructured":"Piening S, Haaijer-Ruskamp FM, de Vries JTN, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf. 2012;35:373\u201385. https:\/\/doi.org\/10.2165\/11599100-000000000-00000.","journal-title":"Drug Saf"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","volume":"50","author":"SB Dusetzina","year":"2012","unstructured":"Dusetzina SB, Higashi AS, Dorsey ER, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012;50:466\u201378. https:\/\/doi.org\/10.1097\/MLR.0b013e318245a160.","journal-title":"Med Care"},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/bcp.14104","volume":"86","author":"CJ Weatherburn","year":"2020","unstructured":"Weatherburn CJ, Guthrie B, Dreischulte T, et al. Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: systematic review, time series analysis and meta-analysis. Br J Clin Pharmacol. 2020;86:698\u2013710. https:\/\/doi.org\/10.1111\/bcp.14104.","journal-title":"Br J Clin Pharmacol"},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pds.4968","volume":"29","author":"U Georgi","year":"2020","unstructured":"Georgi U, L\u00e4mmel J, Datzmann T, et al. Do drug-related safety warnings have the expected impact on drug therapy? A systematic review. Pharmacoepidemiol Drug Saf. 2020;29:229\u201351. https:\/\/doi.org\/10.1002\/pds.4968.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40264-019-00840-3","volume":"42","author":"JT DeFrank","year":"2019","unstructured":"DeFrank JT, McCormack L, West SL, et al. Unintended effects of communicating about drug safety issues: a critical review of the literature. Drug Saf. 2019;42:1125\u201334. https:\/\/doi.org\/10.1007\/s40264-019-00840-3.","journal-title":"Drug Saf"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"1090707","DOI":"10.3389\/fphar.2023.1090707","volume":"14","author":"E Montan\u00e9","year":"2023","unstructured":"Montan\u00e9 E, Santesmases J. Characteristics of drug safety alerts issued by the Spanish Medicines Agency. Front Pharmacol. 2023;14:1090707. https:\/\/doi.org\/10.3389\/fphar.2023.1090707.","journal-title":"Front Pharmacol"},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.clinthera.2015.07.015","volume":"37","author":"S Soares","year":"2015","unstructured":"Soares S, Roque F, Teixeira Rodrigues A, et al. Safety alerts: an observational study in Portugal. Clin Ther. 2015;37:2122\u20138. https:\/\/doi.org\/10.1016\/j.clinthera.2015.07.015.","journal-title":"Clin Ther"},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40264-022-01230-y","volume":"45","author":"E De Vries","year":"2022","unstructured":"De Vries E, Bakker E, Monster TBM, et al. Factors influencing preferences and responses towards drug safety communications: a conjoint experiment among hospital-based healthcare professionals in the Netherlands. Drug Saf. 2022;45:1369\u201380. https:\/\/doi.org\/10.1007\/s40264-022-01230-y.","journal-title":"Drug Saf"},{"key":"573_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.680","volume":"8","author":"A Hooimeyer","year":"2020","unstructured":"Hooimeyer A, Bhasale A, Perry L, et al. Regulatory post-market drug safety advisories on cardiac harm: a comparison of four national regulatory agencies. Pharmacol Res Perspect. 2020;8: e00680. https:\/\/doi.org\/10.1002\/prp2.680.","journal-title":"Pharmacol Res Perspect"},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/pds.4762","volume":"28","author":"M Torka","year":"2019","unstructured":"Torka M, Mintzes B, Bhasale A, et al. Secret safety warnings on medicines: a case study of information access requests. Pharmacoepidemiol Drug Saf. 2019;28:551\u20135. https:\/\/doi.org\/10.1002\/pds.4762.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"573_CR19","unstructured":"Norwegian Institute of Public Health, WHO Collaborating Centre for Drug Statistics Methodology. The ATC\/DDD system. https:\/\/atcddd.fhi.no\/. Accessed 23 Mar 2024."},{"key":"573_CR20","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA\u00ae, the Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org\/. Accessed 23 Mar 2024."},{"key":"573_CR21","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Freedom of information (FOI) 2022. https:\/\/www.tga.gov.au\/about-tga\/legislation\/freedom-information-foi. Accessed 11 Nov 2024."},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2288-9-34","volume":"9","author":"T Merlin","year":"2009","unstructured":"Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian \u201clevels of evidence.\u201d BMC Med Res Methodol. 2009;9:34. https:\/\/doi.org\/10.1186\/1471-2288-9-34.","journal-title":"BMC Med Res Methodol"},{"key":"573_CR23","unstructured":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. 2010. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-ongoing-safety-review-actos-pioglitazone-and-potential-increased-risk. Accessed 7 Sept 2024."},{"key":"573_CR24","unstructured":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. FDA drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. 2011. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-update-ongoing-safety-review-actos-pioglitazone-and-increased-risk. Accessed 7 Sept 2024."},{"key":"573_CR25","unstructured":"Government of Canada, Health Canada. Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer: recalls, advisories and safety alerts. 2011. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/health-canada-reviewing-diabetes-drug-pioglitazone-actos-and-potential-risk-bladder. Accessed 7 Sept 2024."},{"key":"573_CR26","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Pioglitazone and risk of bladder cancer. 2011. https:\/\/www.tga.gov.au\/news\/safety-alerts\/pioglitazone-and-risk-bladder-cancer. Accessed 7 Sept 2024."},{"key":"573_CR27","unstructured":"Medicines and Healthcare products Agency. New advice on risk of bladder cancer with the anti-diabetic drug pioglitazone (Actos, Competact). UK 2011. https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20141205201154\/http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/CON123285. Accessed 7 Sept 2024."},{"key":"573_CR28","unstructured":"United States Food and Drug Administration, Center for Drug Evaluation and Research. FDA drug safety communication: updated drug labels for pioglitazone-containing medicines. 2011. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-drug-labels-pioglitazone-containing-medicines. Accessed 7 Sept 2024."},{"key":"573_CR29","unstructured":"United Kingdom Government, Medicines and Healthcare products Regulatory Agency. Pioglitazone: risk of bladder cancer. 2011. https:\/\/www.gov.uk\/drug-safety-update\/pioglitazone-risk-of-bladder-cancer. Accessed 7 Sept 2024."},{"key":"573_CR30","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Pioglitazone and risk of bladder cancer. Medicines safety update Vol 2, No 5, October 2011. 2011. https:\/\/web.archive.org\/web\/20201020142806\/https:\/\/www.tga.gov.au\/publication-issue\/medicines-safety-update-vol-2-no-5-october-2011. Accessed 7 Sept 2024."},{"key":"573_CR31","unstructured":"Government of Canada, Health Canada. ACTOS (pioglitazone hydrochloride): potential association with bladder cancer: for health professionals. 2012. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/actos-pioglitazone-hydrochloride-potential-association-bladder-cancer-health. Accessed 7 Sept 2024."},{"key":"573_CR32","unstructured":"Government of Canada, Health Canada. ACTOS (pioglitazone hydrochloride): potential association with bladder cancer: for the public. 2012. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/actos-pioglitazone-hydrochloride-potential-association-bladder-cancer-public. Accessed 7 Sept 2024."},{"key":"573_CR33","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Pioglitazone risk-benefit review: medicines safety update, Volume 4, Number 6, December 2013. 2013. https:\/\/web.archive.org\/web\/20211022223353\/https:\/\/www.tga.gov.au\/publication-issue\/medicines-safety-update-volume-4-number-6-december-2013. Accessed 7 Sept 2024."},{"key":"573_CR34","unstructured":"United Kingdom Medicines and Healthcare products Agency. Direct healthcare professional communication on pioglitazone and a small increased risk of urinary bladder cancer (26 July 2011). 2011. https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20141204133950mp_\/http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/websiteresources\/con125969.pdf. Accessed 7 Sept 2024."},{"key":"573_CR35","unstructured":"United Kingdom Medicines and Healthcare products Agency. Direct healthcare professional communication on pioglitazone and a small increased risk of urinary bladder cancer (19 January 2012). 2012. https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20141206114634mp_\/http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/websiteresources\/con143510.pdf. Accessed 7 Sept 2024."},{"key":"573_CR36","unstructured":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. FDA drug safety communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. 2016. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone. Accessed 20 Sept 2024."},{"key":"573_CR37","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Documents relating to Actos (014-1314), released 6 March 2014, foi-014-1314-09. Doc released Sect 11C Freedom of Information Act 1982 Jul 2013 Jun 2014. https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-014-1314-09.pdf. Accessed 12 Oct 2024."},{"key":"573_CR38","unstructured":"Australian Government. Freedom of Information Act 1982. Fed Regist Legis 2024. https:\/\/www.legislation.gov.au\/C2004A02562\/latest. Accessed 17 Nov 2024."},{"key":"573_CR39","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Freedom of Information. FOI 25-0051\u2014Notice of Decision 2024."},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2337\/dc10-1068","volume":"34","author":"JD Lewis","year":"2011","unstructured":"Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone. Diabetes Care. 2011;34:916\u201322. https:\/\/doi.org\/10.2337\/dc10-1068.","journal-title":"Diabetes Care"},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","volume":"55","author":"A Neumann","year":"2012","unstructured":"Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953\u201362. https:\/\/doi.org\/10.1007\/s00125-012-2538-9.","journal-title":"Diabetologia"},{"key":"573_CR42","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9.","journal-title":"Lancet"},{"key":"573_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2165\/11316510-000000000-00000","volume":"32","author":"KG Tolman","year":"2009","unstructured":"Tolman KG, Freston JW, Kupfer S, et al. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32:787\u2013800. https:\/\/doi.org\/10.2165\/11316510-000000000-00000.","journal-title":"Drug Saf"},{"key":"573_CR44","unstructured":"European Medicines Agency. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact (2011). 2011. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000285\/WC500126656.pdf. Accessed Sept 2024."},{"key":"573_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265. https:\/\/doi.org\/10.1001\/jama.2015.7996.","journal-title":"JAMA"},{"key":"573_CR46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/dom.12608","volume":"18","author":"E Erdmann","year":"2016","unstructured":"Erdmann E, Harding S, Lam H, et al. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 2016;18:266\u201373. https:\/\/doi.org\/10.1111\/dom.12608.","journal-title":"Diabetes Obes Metab"},{"key":"573_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1541","volume":"352","author":"M Tuccori","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352: i1541. https:\/\/doi.org\/10.1136\/bmj.i1541.","journal-title":"BMJ"},{"key":"573_CR48","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Documents relating to Actos (014-1314), released 6 March 2014, foi-014-1314-02. Doc released Sect 11C Freedom Information Act 1982 Jul 2013 Jun 2014. https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-014-1314-02.pdf. Accessed 12 Oct 2024."},{"key":"573_CR49","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Documents relating to Actos (014-1314), released 6 March 2014, foi-014-1314-12. Doc released Sect 11C Freedom Information Act 1982 Jul 2013 Jun 2014. https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-014-1314-12.pdf. Accessed 12 Oct 2024."},{"key":"573_CR50","doi-asserted-by":"publisher","first-page":"e036498","DOI":"10.1136\/bmjopen-2019-036498","volume":"10","author":"M-MG H\u00f8jer","year":"2020","unstructured":"H\u00f8jer M-MG, De Bruin ML, Boskovic A, et al. Are monitoring instructions provided in direct healthcare professional communications (DHPCs) of sufficient quality? A retrospective analysis of DHPCs sent out between 2007 and 2018. BMJ Open. 2020;10:e036498. https:\/\/doi.org\/10.1136\/bmjopen-2019-036498.","journal-title":"BMJ Open"},{"key":"573_CR51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/pds.5508","volume":"31","author":"A Kemp-Casey","year":"2022","unstructured":"Kemp-Casey A, Mintzes B, Morrow RL, et al. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: an interrupted time series study. Pharmacoepidemiol Drug Saf. 2022;31:1039\u201345. https:\/\/doi.org\/10.1002\/pds.5508.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"573_CR52","unstructured":"Australian Government Department of Health Therapeutic Goods Administration (TGA). Safety updates: medicines safety updates and medical devices safety updates 2021. https:\/\/www.tga.gov.au\/news\/safety-updates. Accessed 18 May 2025."},{"key":"573_CR53","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Potential signals of serious risks\/new safety information identified from the FDA Adverse Event Reporting System (FAERS). 2025. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event-reporting-system. Accessed 18 May 2025."},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/pds.1319","volume":"15","author":"C Hirst","year":"2006","unstructured":"Hirst C, Cook S, Dai W, et al. A call for international harmonization in therapeutic risk management. Pharmacoepidemiol Drug Saf. 2006;15:839\u201349. https:\/\/doi.org\/10.1002\/pds.1319.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","volume":"33","author":"S Olsson","year":"2010","unstructured":"Olsson S, Pal SN, Stergachis A, et al. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33:689\u2013703. https:\/\/doi.org\/10.2165\/11536390-000000000-00000.","journal-title":"Drug Saf"},{"key":"573_CR56","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamainternmed.2019.0294","volume":"179","author":"G Dal Pan","year":"2019","unstructured":"Dal Pan G. Gauging the effectiveness of medicines safety communications from global regulatory agencies. JAMA Intern Med. 2019;179:984. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0294.","journal-title":"JAMA Intern Med"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-025-00573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-025-00573-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-025-00573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T02:46:42Z","timestamp":1758163602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-025-00573-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s40290-025-00573-y","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"type":"print","value":"1178-2595"},{"type":"electronic","value":"1179-1993"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"3 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This work was support by grants from the National Health and Medical Research Council (APP 1122332) and Canadian Institutes of Health Research (PJT-153275).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lucy T. Perry is an employee of the New South Wales Ministry of Health (Australia) and has no other competing interests to disclose. Barbara Mintzes has acted as an expert witness for Health Canada on a case involving marketing of an unapproved drug product and is an expert witness for the Therapeutic Goods Administration on an Administrative Review Tribunal challenge of a regulatory decision; she has no other competing interests to declare. Alice Bhasale, Ashleigh Hooimeyer, Eliza J. McEwin and Annim Mohammad have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LP contributed to the study design, data collection, data analysis and drafting the manuscript. AB contributed to the study design, data collection, and review and editing of the manuscript. AH, EM and AM contributed to the data collection, and review and editing of the manuscript. BM contributed to the study design, data analysis and review and editing of the manuscript. All the authors have read and approved the final submitted manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}